Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of panobinostat in participants with primary myelofibrosis (terminated; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera | Phase 2 | Status: TERMINATED | Results posted: 2021-07-30